Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

More on protein farnesyltransferase inhibitors in development at Merck

June 1, 1999

Chinese scientists discover new MDR reversal agents during search for cardiovascular agents

June 1, 1999

Recombinant enzyme plus gene therapy: a unique combination therapy for cancer

May 31, 1999

CPMP recommends expanded approval of Temodal for brain tumor therapy

May 31, 1999

Ilex initiates clinical testing of vitamin D3 analogue

May 31, 1999

EntreMed announces sites for Endostatin phase I clinical trials

May 31, 1999

More news from ASCO: safety and pharmacokinetics of squalamine examined in phase I trials

May 28, 1999

Survival advantage for exemestane observed in phase III breast cancer trial reported at ASCO meeting

May 28, 1999

DNA ligase inhibitors with alpha-pyrone structure in development at Millennium

May 28, 1999

Alza submits NDA for Viadur prostate cancer treatment

May 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.